Fig. 3: RPL22L1 induces mesenchymal phenotype in GBM. | Cell Death & Disease

Fig. 3: RPL22L1 induces mesenchymal phenotype in GBM.

From: RPL22L1, a novel candidate oncogene promotes temozolomide resistance by activating STAT3 in glioblastoma

Fig. 3: RPL22L1 induces mesenchymal phenotype in GBM.The alternative text for this image may have been generated using AI.

A Kaplan-Meier overall survival analysis of xenograft tumor in nude mice with Log-rank test, P-values indicated (n = 10). B Representative H&E and IHC RPL22L1 staining images (magnification × 400, scale bar = 50 μm) in section of xenograft tumors induced with LN229-RPL22L1 and control cells were shown. C The expressions of N-cadherin and Vimentin in GBM cells were detected by Western Blot, GAPDH was used as the internal control. D Representative images of IHC staining for clinical GBM tissues showed the expressions of RPL22L1, N-cadherin and Vimentin (left, magnification × 400, scale bar = 50 μm). Case 1: GBM with low RPL22L1 expression; Case 2: GBM with high RPL22L1 expression. According to the staining scores to analyze the correlations between RPL22L1 and N-cadherin, Vimentin (right, Pearson correlation analysis, n = 7). E Western Blot was used to analyze the expressions of N-cadherin and Vimentin in clinical GBM tissues and paired adjacent tissues (left, n = 6). Protein gray scale analysis of the correlations between RPL22L1, N-cadherin and Vimentin (right, Pearson correlation analysis, n = 6). F IHC staining of RPL22L1, N-cadherin and Vimentin in normal brain tissues and GBM tissues in TMAs (left, magnification × 400, scale bar = 50 μm). According to the staining scores to analyze the correlations between RPL22L1 and N-cadherin, Vimentin expressions (right, Pearson correlation analysis) in normal brain tissues (n = 3) and GBM brain tissues (n = 32).

Back to article page